Form 4: Celldex Exec Sells Shares Under 10b5-1 Plan

Celldex Therapeutics' SVP & General Counsel, Freddy A. Jimenez, sold 771 shares of common stock through a pre-arranged trading plan.

Summary

• Freddy A. Jimenez, SVP & General Counsel of Celldex Therapeutics, Inc. (CLDX), reported sales of company common stock.
• On August 13, 2025, Jimenez sold 341 shares at a price of $23.9515 per share.
• On the same date, an additional 430 shares were sold at $25.415 per share.
• These transactions were conducted under a Rule 10b5-1(c) pre-arranged trading plan.
• Following these sales, Jimenez beneficially owns 34,962 shares of Celldex common stock.
• The reported beneficial ownership includes 269 shares acquired through the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: Neutral. The filing reports routine insider stock sales under a pre-arranged 10b5-1 plan, which is a common practice for executives and does not typically signal a change in company fundamentals or outlook.

Positives

• The sales were conducted under a Rule 10b5-1(c) plan, indicating they were pre-scheduled and not based on immediate, non-public information.

Negatives

• An insider selling shares can sometimes be perceived as a negative signal, although the 10b5-1 plan mitigates this concern.

Future Outlook

NA

Industry Context

This is a routine insider transaction for a biotechnology company. Such sales, especially under 10b5-1 plans, are common for executives managing their personal portfolios and are generally not indicative of company-specific issues or broader industry trends.

Stakeholder Impact

• Shareholders: The sale of shares by an executive, even under a 10b5-1 plan, slightly reduces the executive's direct alignment with shareholder interests, though the impact is minimal given the routine nature and remaining significant holdings.

Key Dates

Recommendation

The filing details a routine insider stock sale by an executive under a pre-arranged 10b5-1 plan. This type of transaction is common for executives managing their personal finances and is generally not indicative of any new material information about the company's performance or future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Celldex Therapeutics, CLDX, Insider Trading, Form 4, Stock Sale, Freddy A. Jimenez, 10b5-1 Plan, Biotechnology, Pharmaceuticals